# Digital Breast Tomosynthesis Market

> Digital Breast Tomosynthesis (DBT) Market Research Report: Size, Share, Trend Analysis By Product (2D/3D Combo and 3D-Only), by Configuration (U-Arm and Others), By Applications (Breast Cancer Screening and Diagnostic Imaging), by End-User (Hospitals and Specialty Clinics, Diagnostic Imaging Centers, Research & Academic Institute) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.68%
- **2024:** $ 3,880 Million
- **2025:** $ 4,333.18 Million
- **2035:** $ 13,078.6 Million
- **Key Players:** Hologic (US), GE Healthcare (US), Siemens Healthineers (DE), Philips (NL), Fujifilm (JP), Canon Medical Systems (JP), Carestream Health (US), Konica Minolta (JP), Agfa HealthCare (BE)

**Report ID:** MRFR/HC/63830-CR · **Pages:** 201 · **Author:** Rahul Gotadki · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/digital-breast-tomosynthesis-market-60427

---

## Market Summary

## **Digital Breast Tomosynthesis (DBT) Market Overview**

The Digital Breast Tomosynthesis (DBT) Market was valued at USD 3.88 billion in 2024. The Digital Breast Tomosynthesis (DBT) Market industry is projected to grow from USD 4.37 billion in 2025 to USD 13.18 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.68% during the forecast period (2025-2035).

The increasing prevalence of breast cancer and technological advancements and shift toward early and preventive diagnosis are driving the growth of the Digital Breast Tomosynthesis (DBT) Market.

As per the Analyst at MRFR, the rising global prevalence of breast cancer is a key driver behind the rapid growth of the digital breast tomosynthesis (DBT) market. According to the WHO, in 2022 alone, 2.3 million women were diagnosed with breast cancer, and 670,000 died from the disease, underscoring the critical need for early and accurate detection.

In the U.S., the National Breast Cancer Foundation, Inc. reports that 1 in 8 women will be diagnosed with breast cancer in their lifetime, with 316,950 women and 2,800 men expected to be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive (in situ) breast cancer. 

These alarming statistics have intensified demand for advanced screening technologies like 3D mammography (tomosynthesis), which offers higher detection rates and fewer false positives compared to traditional 2D mammography. Governments and healthcare providers are increasingly adopting DBT in screening programs, while technological advancements and growing awareness further propel market expansion.

 **FIGURE 1: DIGITAL BREAST TOMOSYNTHESIS (DBT) MARKET VALUE (2019-2035) USD BILLION**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

## **Digital Breast Tomosynthesis (DBT) Market****Opportunity**

### **EXPANSION INTO EMERGING MARKETS**

Expansion into emerging markets is creating significant and lucrative growth opportunities for the global tomosynthesis market. Developing regions such as Asia-Pacific, Latin America, and parts of the Middle East and Africa are experiencing a surge in breast cancer incidence, coupled with growing awareness of the importance of early detection and diagnosis. Governments in these regions are increasingly investing in healthcare infrastructure, initiating national screening programs, and encouraging the adoption of advanced imaging technologies like digital breast tomosynthesis (DBT).

As per India’s Union Budget 2025, the government’s strong push for private sector participation supported by regulatory reforms and a USD 1,756.83 infrastructure boost—is set to unlock new avenues for innovation and investment. 

The proposed AI Development Center, along with regional skilling hubs developed through global collaborations, aims to modernise healthcare delivery and diagnostics across the country. Additionally, the rising middle-class population and improving healthcare access are boosting demand for high-quality diagnostic services. Medical device manufacturers are recognizing the untapped potential in these markets and are strategically expanding through partnerships, localized manufacturing, and cost-effective solutions tailored to regional needs. As a result, emerging markets are becoming key growth drivers, offering new revenue streams and accelerating the global adoption of tomosynthesis systems.

## **Digital Breast Tomosynthesis (DBT) Market****Segment Insights**

### **Digital Breast Tomosynthesis (DBT)****by Product Insights**

Based on Product, this segment includes 2D/3D Combo and 3D-Only. The 2D/3D Combo segment dominated the global market in 2024, while the 3D-Only segment is projected to be the fastest–growing segment during the forecast period. The 2D/3D combination mammogram is an advanced method for breast cancer screening that uses both traditional 2D mammography and 3D tomosynthesis. The 2D mammogram captures a standard image of the breast from two angles, while the 3D tomosynthesis takes multiple images from different angles and puts them together to create a detailed 3D picture. 

This combination helps doctors find problems more accurately, especially in women with dense breast tissue where 2D images might miss some issues. The 2D/3D combo also reduces the chances of false positives, meaning fewer women will need unnecessary follow-up tests. While there’s a slight increase in radiation exposure compared to a regular 2D mammogram, the extra clarity and accuracy make it a valuable tool for early breast cancer detection.

**FIGURE 2: DIGITAL BREAST TOMOSYNTHESIS (DBT) MARKET SHARE BY PRODUCT 2024 AND 2035 (USD BILLION)**

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

### **Digital Breast Tomosynthesis (DBT)****by Configuration Insights**

Based on Configuration, this segment includes U-Arm and Others. The Others segment dominated the global market in 2024, while the U-Arm segment is projected to be the fastest–growing segment during the forecast period. C-arm tomosynthesis devices are emerging as a valuable innovation in the breast cancer diagnostics, offering high-resolution 3D imaging that significantly enhances the accuracy of tumor detection and characterization. 

Unlike conventional 2D mammography, tomosynthesis captures multiple images from different angles, allowing radiologists to examine breast tissue in thin slices and identify malignancies that may be obscured in dense tissue. These systems are particularly beneficial in biopsy guidance and intraoperative imaging, enabling precise localization and assessment of lesions. As healthcare providers seek to improve early detection rates and reduce recall rates, the demand for C-arm tomosynthesis solutions tailored to breast cancer applications is growing steadily, supported by advancements in imaging technology and increased focus on patient-centered care.

### **Digital Breast Tomosynthesis (DBT)****by Application Insights**

Based on Application, this segment includes Breast Cancer Screening and Diagnostic Imaging. The [**Breast Cancer**](../../../reports/global-breast-cancer-market-1379) Screening segment dominated the global market in 2024, while the Diagnostic Imaging segment is projected to be the fastest–growing segment during the forecast period. The use of tomosynthesis in breast cancer screening is revolutionizing community health methods by boosting early detection rates, particularly in women with thick breast tissue. 

As a screening modality, 3D tomosynthesis greatly reduces recall rates and false positives, hence improving clinical workflow and lowering downstream costs associated with unnecessary follow-up imaging. Healthcare providers who use tomosynthesis for routine screening gain a competitive advantage by providing patients with more accurate and comfortable scans, generally with equivalent or lower radiation exposure than when synthetic 2D pictures are used. Strategically, investing in DBT promotes quality-based care initiatives, improves compliance with breast screening standards, and reinforces a facility's reputation for providing advanced, patient-centered diagnostics.

### **Digital Breast Tomosynthesis (DBT)****by End-User Insights**

Based on End-User, this segment includes Hospitals and Specialty Clinics, Diagnostic Imaging Centers, Research & Academic Institute. The Hospitals and Specialty Clinics segment dominated the global market in 2024, while the Diagnostic Imaging Centers segment is projected to be the fastest–growing segment during the forecast period. Hospitals and specialty clinics are representing important end-user sectors in the tomosynthesis industry, with each playing a crucial role in its continued expansion. 

Hospitals dominate the market because of their extensive diagnostic infrastructure, ability to handle large patient volumes, and integration of modern imaging technologies into multidisciplinary treatment pathways. Their investment in DBT is consistent with larger institutional aims such as improving diagnostic accuracy, patient outcomes, and satisfying value-based care criteria. In parallel, specialized clinics, particularly imaging and women's health centers, emerging as significant providers, utilizing DBT to provide accessible, early detection services in outpatient settings. Their focused service delivery strategy and smaller operating costs allow for rapid adoption of new technologies, positioning them as significant drivers of market expansion and innovation.

### **Digital Breast Tomosynthesis (DBT)****Regional Insights**

Based on the Region, the global Digital Breast Tomosynthesis (DBT) are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa. The North America dominated the global market in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are the increasing prevalence of breast cancer and technological advancements and shift toward early and preventive diagnosis. 

The North American tomosynthesis market is expanding rapidly, driven by a number of major factors such as rising breast cancer rates, technological improvements, and increased need for more precise diagnostic techniques. For example, the prevalence of breast cancer in North America is rising. According to the American Cancer Society, approximately one out of every eight women in the United States may acquire breast cancer over their lifetime. 

This has resulted in increased adoption of advanced screening methods, such as tomosynthesis, which improves early detection rates. The increased awareness of breast cancer, combined with updated screening standards, is encouraging healthcare professionals to use digital breast tomosynthesis (DBT) as a tool to improve early diagnosis and eliminate false positives often associated with traditional mammography.

**FIGURE 3: DIGITAL BREAST TOMOSYNTHESIS (DBT) MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.

## **Digital Breast Tomosynthesis (DBT) Key Market Players & Competitive Insights**

Many global, regional, and local vendors characterize the Digital Breast Tomosynthesis (DBT) Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major competitors in the market are Hologic, Inc., GE HealthCare, FUJIFILM Holdings Corporation, Trivitron Healthcare Private Limited, Planmed Oy, Siemens Healthineers, PerkinElmer, Canon Medical Systems Corporation, Analogic Corporation, Shimadzu Corporation, NP JSC AMICO, VMI Médica, BEMEMS Co., Ltd., Sino Medical-Device Technology Co., Ltd., Shenzhen Landwind Industry Co., Payamed Electronic Industries Co., Medical Technologies Ltd. (MTL), Metaltronica S.p.A., Lotus Healthcare, Koninklijke Philips N.V., Allengers Medical Systems Ltd., IMS Giotto S.p.A., Shenzhen Angell Technology Co., Ltd., Konica Minolta, Inc., Electron Co. are among others.

The Digital Breast Tomosynthesis (DBT) Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

### **Key Companies in the****Digital Breast Tomosynthesis (DBT) Market****include**

- Hologic, Inc.
- GE HealthCare
- [FUJIFILM Holdings Corporation](https://www.fujifilm.com/in/en/healthcare/innomuse/breastimaging_mammography)
- Trivitron Healthcare Private Limited
- Planmed Oy
- Siemens Healthineers
- PerkinElmer
- Canon Medical Systems Corporation
- Analogic Corporation
- Shimadzu Corporation
- NP JSC AMICO
- VMI Médica
- BEMEMS Co., Ltd.
- Sino Medical-Device Technology Co., Ltd.
- Shenzhen Landwind Industry Co.
- Payamed Electronic Industries Co.
- Medical Technologies Ltd. (MTL)
- Metaltronica S.p.A.
- Lotus Healthcare
- Koninklijke Philips N.V.
- Allengers Medical Systems Ltd.
- IMS Giotto S.p.A.
- Shenzhen Angell Technology Co., Ltd.
- Konica Minolta, Inc.
- Electron Co.

## **Digital Breast Tomosynthesis (DBT) Market****Industry Developments**

**January 2025:** Siemens Healthineers announced the first U.S. installation of its Mammomat B.brilliant mammography system. GRACE Breast Imaging & Medical Spa of Iowa, with locations in Urbandale and Clive, became the first healthcare facility in the United States to install the new Mammomat B.brilliant. The system featured advanced 3D image acquisition and reconstruction technology, along with capabilities for full-field digital mammography (2D breast imaging), breast biopsy, and titanium contrast-enhanced mammography.

**September 2024:** The FDA granted expanded approval for Siemens Healthineers' mammography platform for digital breast tomosynthesis. The approval included the integration of UltraHD technology for image reconstruction, which enhanced calcification visualization, reduced metal artifacts, and enabled the generation of synthetic 2D images without subjecting patients to additional radiation.

**September 2023:** Hologic and Bayer announced a global collaboration to offer an integrated solution for contrast-enhanced mammography (CEM). This partnership combines Hologic’s advanced mammography systems and imaging technologies with Bayer’s contrast media and injector systems. The goal is to provide radiologists with a streamlined, high-performance CEM solution that improves the detection of breast cancer, especially in women with dense breast tissue. This collaboration enhances diagnostic accuracy by allowing better visualization of lesions and vascularization, bridging the gap between traditional mammography and MRI. It also supports workflow efficiency and standardization across breast imaging facilities globally.

**August 2020:** Canon Medical Systems USA, Inc. partnered with Zebra Medical Vision to integrate its AI1 automated imaging analysis solutions into clinical workflows across the U.S., aiming to support faster and more accurate diagnoses for improved patient care. Zebra Medical’s AI1 platform, powered by FDA-cleared, cloud-based AI algorithms trained on hundreds of millions of patient scans, was designed to triage acute conditions, identify incidental findings, and stratify patient risk. This collaboration marked Zebra Medical’s entry into the modality space, bringing advanced AI capabilities closer to the point of care and enhancing diagnostic efficiency within imaging systems.

## **Digital Breast Tomosynthesis (DBT) Market****Segmentation**

### **Digital Breast Tomosynthesis (DBT) by Product Outlook**

- 2D/3D Combo
- 3D-Only

### **Digital Breast Tomosynthesis (DBT) by Configuration Outlook**

- U-Arm
- Others

### **Digital Breast Tomosynthesis (DBT) by Application Outlook**

- Breast Cancer Screening
- Diagnostic Imaging

### **Digital Breast Tomosynthesis (DBT) by End-User Outlook**

- Hospitals and Specialty Clinics
- Diagnostic Imaging Centers
- Research & Academic Institute

### **Digital Breast Tomosynthesis (DBT)****Regional Outlook**

- North America - US - Canada
- Europe - Germany - France - UK - Italy - Spain - Russia - Rest of Europe
- Asia-Pacific - China - India - Japan - South Korea - Malaysia - Thailand - Indonesia - Rest of Asia-Pacific
- South America - Brazil - Mexico - Argentina - Rest of South America
- Middle East & Africa - GCC Countries - South Africa - Rest of Middle East and Africa

## Market Drivers

### Regulatory Support

Regulatory support plays a crucial role in the growth of the Digital Breast Tomosynthesis Market. Various health authorities are increasingly recognizing the benefits of digital breast tomosynthesis in breast cancer screening and diagnosis. For instance, the approval of new tomosynthesis devices by regulatory bodies has facilitated their entry into the market, thereby expanding the options available to healthcare providers. This regulatory backing not only boosts confidence among manufacturers but also encourages investment in research and development. As a result, the market is likely to see a rise in the number of innovative products aimed at improving breast cancer detection. Furthermore, favorable reimbursement policies for digital breast tomosynthesis procedures are expected to enhance accessibility, thereby driving market growth.

### Technological Advancements

The Digital Breast Tomosynthesis Market is experiencing rapid technological advancements that enhance imaging capabilities. Innovations such as improved detector technology and advanced image reconstruction algorithms are leading to higher resolution images and reduced radiation exposure. These advancements are likely to increase the adoption of digital breast tomosynthesis systems among healthcare providers. According to recent data, the market for digital breast tomosynthesis systems is projected to grow at a compound annual growth rate of approximately 20% over the next five years. This growth is driven by the increasing demand for early detection of breast cancer and the need for more accurate diagnostic tools. As technology continues to evolve, the Digital Breast Tomosynthesis Market is expected to witness further enhancements that could improve patient outcomes.

### Increased Awareness and Education

Increased awareness and education regarding breast cancer screening are pivotal drivers for the Digital Breast Tomosynthesis Market. Campaigns aimed at educating the public about the importance of early detection have led to a rise in screening rates. As more women become informed about the advantages of digital breast tomosynthesis over traditional mammography, the demand for these advanced imaging techniques is likely to increase. Educational initiatives by healthcare organizations and non-profits are also contributing to this trend. Data indicates that regions with higher awareness levels have seen a significant uptick in the utilization of digital breast tomosynthesis, suggesting a correlation between education and market growth. This heightened awareness is expected to continue influencing the Digital Breast Tomosynthesis Market positively.

### Rising Incidence of Breast Cancer

The rising incidence of breast cancer is a significant driver for the Digital Breast Tomosynthesis Market. As breast cancer rates continue to increase, there is a growing need for effective screening and diagnostic tools. Digital breast tomosynthesis offers enhanced detection capabilities, particularly in women with dense breast tissue, which is a common challenge in traditional mammography. Recent statistics indicate that breast cancer remains one of the most prevalent cancers among women, prompting healthcare systems to adopt more advanced imaging technologies. This trend is likely to propel the demand for digital breast tomosynthesis systems, as healthcare providers seek to improve diagnostic accuracy and patient outcomes. Consequently, the Digital Breast Tomosynthesis Market is expected to expand in response to this pressing healthcare need.

### Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is another critical driver for the Digital Breast Tomosynthesis Market. As countries prioritize healthcare improvements, there is a notable increase in funding for advanced diagnostic technologies. This investment is particularly evident in the establishment of specialized breast imaging centers equipped with state-of-the-art digital breast tomosynthesis systems. Enhanced healthcare infrastructure not only facilitates the adoption of new technologies but also improves patient access to quality care. Furthermore, partnerships between public and private sectors are likely to foster innovation and expedite the deployment of digital breast tomosynthesis solutions. As a result, the Digital Breast Tomosynthesis Market is poised for growth, driven by these infrastructural advancements.

## Future Outlook

The Digital Breast Tomosynthesis Market is projected to grow at 11.68% CAGR from 2024 to 2035, driven by technological advancements, increasing breast cancer awareness, and rising demand for early detection.

**New opportunities:**

- Development of AI-driven diagnostic software for enhanced image analysis. Expansion of mobile tomosynthesis units for rural healthcare access. Partnerships with insurance providers to improve reimbursement models.

By 2035, the market is expected to achieve substantial growth, solidifying its role in breast cancer detection.

## Segment Insights

### By Application: Screening (Largest) vs. Diagnostic (Fastest-Growing)

In the Digital Breast Tomosynthesis Market, the application segment is primarily driven by screening, which holds the largest market share due to its essential role in early detection of breast cancer. This approach enhances imaging capabilities, leading to better diagnostic accuracy and, ultimately, improving patient outcomes. The screening application is widely adopted by healthcare facilities to meet increasing demands, supported by ongoing advancements in imaging technology. In contrast, the diagnostic application is emerging as the fastest-growing segment. This growth is fueled by rising awareness about breast cancer, leading to higher demand for conclusive imaging techniques. Enhanced technology for more precise diagnosis is pushing diagnostic tomosynthesis to the forefront, with healthcare providers increasingly incorporating it into their standard protocols, thereby expanding its footprint in the market.

Screening (Dominant) vs. Diagnostic (Emerging)

The screening application in the Digital Breast Tomosynthesis Market remains dominant due to its crucial role in early intervention and preventive healthcare. It allows radiologists to detect abnormalities not visible in traditional 2D mammography, significantly improving the sensitivity and specificity of breast cancer screenings. Coupled with growing public health initiatives, more women are encouraged to undergo regular screenings. On the other hand, the diagnostic segment, while currently emerging, is rapidly gaining traction. Its focus on providing comprehensive assessments for patients with abnormal findings from screening tests is crucial. Advances in technology and clinical protocols are enhancing its capabilities, positioning diagnostic applications as essential tools in comprehensive breast health management.

### By End Use: Hospitals (Largest) vs. Diagnostic Imaging Centers (Fastest-Growing)

In the Digital Breast Tomosynthesis Market, hospitals represent the largest share, benefiting from their established infrastructure and comprehensive patient care capabilities. These facilities are increasingly adopting advanced imaging technologies, significantly contributing to their dominance in market share. Meanwhile, diagnostic imaging centers are gaining ground, as they specialize in diagnostic services and offer convenience, playing a crucial role in the growing awareness of breast cancer screenings.

Hospitals (Dominant) vs. Diagnostic Imaging Centers (Emerging)

Hospitals serve as the dominant players in the Digital Breast Tomosynthesis Market due to their ability to facilitate extensive patient care and their investment in cutting-edge imaging technologies. They typically possess the resources necessary for adopting advanced digital health solutions, ensuring high-quality imaging services. On the other hand, diagnostic imaging centers are emerging players that provide specialized services tailored for breast cancer diagnosis. Their growth is fueled by the increasing demand for accessible and dedicated imaging services, as well as partnerships with healthcare providers to enhance screening opportunities.

### By Technology: Digital Radiography (Largest) vs. Computed Tomography (Fastest-Growing)

In the Digital Breast [Tomosynthesis](https://www.marketresearchfuture.com/reports/tomosynthesis-market-41329) Market, Digital Radiography holds a significant portion of the market share, establishing itself as the predominant technology. Its widespread adoption in clinical settings demonstrates the robustness of this segment, as it continues to be the preferred method among healthcare professionals due to its effectiveness and efficiency. Conversely, Computed Tomography, while smaller in market share, is gaining ground rapidly due to advancements in imaging technology and increased awareness of its benefits in breast cancer screening and diagnostics. Growth trends in the Digital Breast Tomosynthesis Market are driven by continuous technological innovations and the rising demand for early cancer detection methods. The increasing prevalence of breast cancer globally is pushing healthcare providers to adopt advanced imaging solutions. Additionally, growing investments in healthcare infrastructure are enabling hospitals and clinics to upgrade their diagnostic tools, with Digital Radiography and Computed Tomography being at the forefront of these advancements.

Technology: Digital Radiography (Dominant) vs. Computed Tomography (Emerging)

Digital Radiography is widely recognized as the dominant technology in the Digital Breast Tomosynthesis Market due to its established reliability, cost-effectiveness, and rapid imaging capabilities, making it a staple in breast cancer screening programs. On the other hand, Computed Tomography represents an emerging technology with the potential for significant impact due to its ability to provide detailed cross-sectional images, enhancing the diagnostic process. As healthcare providers increasingly seek comprehensive and accurate imaging solutions, CT technology is rapidly integrating into conventional breast imaging practices. Its advantages, including improved sensitivity and specificity for detecting malignancies, position it as a competitive alternative, particularly in complex cases where traditional methods may fall short.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Digital Breast Tomosynthesis Market, the distribution of patient demographics significantly influences adoption rates and market utilization. The age group segment is the largest, with older populations being primary users of breast imaging technologies. Conversely, the gender segment is rapidly evolving, showing a notable increase in screenings among male patients, reflecting a growing awareness of breast cancer across demographics.

Age Group: 50+ (Dominant) vs. Gender: Male (Emerging)

The age group of 50 years and older is the dominant demographic in the Digital Breast Tomosynthesis Market, driven by targeted breast cancer screening recommendations for women in this age bracket. This segment predominantly seeks advanced imaging techniques to enable early cancer detection and subsequent treatment. Meanwhile, the emerging trend of male patients undergoing breast screenings signifies changing perceptions and increased education about breast health, with an emphasis on inclusivity in diagnostic practices. This emerging demographic offers new opportunities for healthcare providers to expand their services and tailor educational initiatives.

### By Pricing Model: Pay-per-Use (Largest) vs. Subscription-Based (Fastest-Growing)

In the Digital Breast Tomosynthesis Market, the pricing model segmentation reveals distinct preferences among healthcare providers. The Pay-per-Use model holds the largest share due to its flexibility and minimal initial investment barrier, making it favorable for clinics and hospitals that seek to optimize resource allocation without committing to long-term costs. Conversely, the Subscription-Based model has been gaining traction, especially among larger healthcare systems that favor predictable budgeting and ongoing support. This model's increasing market presence reflects a shift towards more integrated healthcare solutions. Growth trends in this segment are primarily driven by the advancements in technology that enhance the capabilities of Digital Breast Tomosynthesis systems. The push for early breast cancer detection is prompting healthcare facilities to invest in innovative solutions that offer better patient outcomes. Additionally, the Subscription-Based model's appeal lies in its scalability and the potential for ongoing software updates, which cater to consumers' desire for the latest technology. These factors collectively signify the evolving landscape of pricing strategies in the market.

Pay-per-Use (Dominant) vs. Subscription-Based (Emerging)

The Pay-per-Use pricing model is currently the dominant approach in the Digital Breast Tomosynthesis Market, favored for its flexibility and lower upfront commitment from healthcare providers. This model allows facilities to utilize advanced breast imaging technology on an as-needed basis, aligning with the varying patient volumes encountered by clinics and hospitals. On the other hand, the Subscription-Based model represents an emerging trend that is rapidly gaining ground. It offers an inclusive package of services, including software updates and technical support, allowing healthcare institutions to stay at the forefront of imaging advancements. This model is particularly appealing to larger facilities with consistent patient loads, as it simplifies budgeting and enhances operational efficiency. As both of these models continue to evolve, they are reshaping the competitive dynamics within the Digital Breast Tomosynthesis Market.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Digital Breast Tomosynthesis market, holding a significant market share of $2100.0M as of 2024. The region's growth is driven by increasing awareness of breast cancer screening, advancements in imaging technology, and supportive regulatory frameworks. The FDA's approval of new tomosynthesis systems has further catalyzed market expansion, enhancing diagnostic accuracy and patient outcomes. The competitive landscape in North America is robust, featuring key players such as Hologic, GE Healthcare, and Siemens Healthineers. These companies are at the forefront of innovation, continuously developing advanced solutions to meet the rising demand for effective breast cancer screening. The presence of established healthcare infrastructure and significant investment in research and development further solidifies North America's position as a market leader.

### Europe : Emerging Market with Growth Potential

Europe's Digital Breast Tomosynthesis market is experiencing significant growth, with a market size of $1100.0M. The increasing incidence of breast cancer and the adoption of advanced imaging technologies are key drivers of this growth. Regulatory bodies are actively promoting early detection initiatives, which are expected to enhance screening rates across the region. The European Commission's focus on improving healthcare access is also a catalyst for market expansion. Leading countries in this region include Germany, France, and the UK, where major players like Siemens Healthineers and Philips are making substantial investments. The competitive landscape is characterized by a mix of established companies and emerging startups, all striving to innovate and capture market share. The presence of strong healthcare systems and funding for medical technology further supports the growth of Digital Breast Tomosynthesis in Europe.

### Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is witnessing a burgeoning demand for Digital Breast Tomosynthesis, with a market size of $550.0M. Factors such as rising awareness of breast cancer, increasing healthcare expenditure, and government initiatives to improve screening rates are driving this growth. Regulatory support for advanced imaging technologies is also enhancing market dynamics, making it a focal point for innovation in breast cancer diagnostics. Countries like Japan, Australia, and China are leading the charge in adopting these technologies. Key players such as Fujifilm and Canon Medical Systems are actively expanding their presence in the region. The competitive landscape is evolving, with both multinational corporations and local firms vying for market share, driven by the need for effective screening solutions in a rapidly growing healthcare environment.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Digital Breast Tomosynthesis market, currently valued at $130.0M. The growth is primarily driven by increasing awareness of breast cancer and the need for advanced diagnostic tools. However, challenges such as limited healthcare infrastructure and varying regulatory environments can hinder market expansion. Efforts by governments to improve healthcare access are crucial for fostering growth in this sector. Countries like South Africa and the UAE are at the forefront of adopting new technologies, with local and international players working to establish a foothold in the market. Companies like Agfa HealthCare are focusing on providing affordable solutions tailored to the region's needs. The competitive landscape is characterized by a mix of established firms and new entrants, all aiming to enhance breast cancer screening capabilities.

## Competitive Benchmarking

The Digital Breast Tomosynthesis Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing emphasis on early breast cancer detection. Key players such as Hologic (US), GE Healthcare (US), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market positioning. Hologic (US) focuses on innovation, particularly in developing advanced imaging technologies that improve diagnostic accuracy. Meanwhile, GE Healthcare (US) emphasizes partnerships with healthcare providers to expand its reach and integrate its solutions into existing healthcare infrastructures. Siemens Healthineers (DE) is leveraging digital transformation initiatives to streamline operations and enhance patient outcomes, thereby shaping a competitive environment that prioritizes technological superiority and operational efficiency.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the Digital Breast Tomosynthesis Market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of offerings, yet the collective impact of major companies like Hologic (US) and GE Healthcare (US) is significant, as they set benchmarks for innovation and service delivery.
In January 2026, Hologic (US) announced the launch of its latest 3D mammography system, which incorporates artificial intelligence (AI) to enhance image analysis. This strategic move is likely to bolster Hologic's competitive edge by providing healthcare professionals with tools that improve diagnostic accuracy and reduce reading times. The integration of AI into imaging systems is indicative of a broader trend towards digitalization in the healthcare sector, which is expected to redefine operational standards.
In December 2025, Siemens Healthineers (DE) entered a strategic partnership with a leading telehealth provider to enhance remote diagnostic capabilities. This collaboration is poised to expand access to tomosynthesis services, particularly in underserved regions, thereby aligning with the growing demand for telehealth solutions. Such partnerships not only enhance service delivery but also position Siemens Healthineers (DE) as a leader in integrating advanced imaging technologies with telehealth platforms.
In November 2025, GE Healthcare (US) unveiled a new initiative aimed at sustainability in its manufacturing processes, focusing on reducing waste and energy consumption. This initiative reflects a growing trend towards environmentally responsible practices within the healthcare sector, which may resonate well with stakeholders increasingly concerned about sustainability. By prioritizing eco-friendly operations, GE Healthcare (US) is likely to enhance its brand reputation and appeal to a broader customer base.
As of February 2026, the Digital Breast Tomosynthesis Market is witnessing trends that emphasize digitalization, sustainability, and AI integration. Strategic alliances are becoming increasingly pivotal, as companies recognize the value of collaborative efforts in enhancing service delivery and operational efficiency. Looking ahead, competitive differentiation is expected to evolve, shifting from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition suggests that companies that prioritize these aspects will likely emerge as leaders in the market.

## Recent News & Developments

**January 2025:** Siemens Healthineers announced the first U.S. installation of its Mammomat B.brilliant mammography system. GRACE Breast Imaging & Medical Spa of Iowa, with locations in Urbandale and Clive, became the first healthcare facility in the United States to install the new Mammomat B.brilliant. The system featured advanced 3D image acquisition and reconstruction technology, along with capabilities for full-field digital mammography (2D breast imaging), breast biopsy, and titanium contrast-enhanced mammography.

**September 2024:** The FDA granted expanded approval for Siemens Healthineers' mammography platform for digital breast tomosynthesis. The approval included the integration of UltraHD technology for image reconstruction, which enhanced calcification visualization, reduced metal artifacts, and enabled the generation of synthetic 2D images without subjecting patients to additional radiation.

**September 2023:** Hologic and Bayer announced a global collaboration to offer an integrated solution for contrast-enhanced mammography (CEM). This partnership combines Hologic’s advanced mammography systems and imaging technologies with Bayer’s contrast media and injector systems. The goal is to provide radiologists with a streamlined, high-performance CEM solution that improves the detection of breast cancer, especially in women with dense breast tissue. This collaboration enhances diagnostic accuracy by allowing better visualization of lesions and vascularization, bridging the gap between traditional mammography and MRI. It also supports workflow efficiency and standardization across breast imaging facilities globally.

**August 2020:** Canon Medical Systems USA, Inc. partnered with Zebra Medical Vision to integrate its AI1 automated imaging analysis solutions into clinical workflows across the U.S., aiming to support faster and more accurate diagnoses for improved patient care. Zebra Medical’s AI1 platform, powered by FDA-cleared, cloud-based AI algorithms trained on hundreds of millions of patient scans, was designed to triage acute conditions, identify incidental findings, and stratify patient risk. This collaboration marked Zebra Medical’s entry into the modality space, bringing advanced AI capabilities closer to the point of care and enhancing diagnostic efficiency within imaging systems.

## **Digital Breast Tomosynthesis Market (DBT) Market****Segmentation**

### **Digital Breast Tomosynthesis Market (DBT) by Product Outlook**

- 2D/3D Combo
- 3D-Only

### **Digital Breast Tomosynthesis Market (DBT) by Configuration Outlook**

- U-Arm
- Others

### **Digital Breast Tomosynthesis Market (DBT) by Application Outlook**

- Breast Cancer Screening
- Diagnostic Imaging

### **Digital Breast Tomosynthesis Market (DBT) by End-User Outlook**

- Hospitals and Specialty Clinics
- Diagnostic Imaging Centers
- Research & Academic Institute

### **Digital Breast Tomosynthesis Market (DBT)****Regional Outlook**

- North America - US - Canada
- Europe - Germany - France - UK - Italy - Spain - Russia - Rest of Europe
- Asia-Pacific - China - India - Japan - South Korea - Malaysia - Thailand - Indonesia - Rest of Asia-Pacific
- South America - Brazil - Mexico - Argentina - Rest of South America
- Middle East & Africa - GCC Countries - South Africa - Rest of Middle East and Africa

## Report Scope

| MARKET SIZE 2024 | 3880.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 4333.18(USD Million) |
| MARKET SIZE 2035 | 13078.6(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.68% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Hologic (US), GE Healthcare (US), Siemens Healthineers (DE), Philips (NL), Fujifilm (JP), Canon Medical Systems (JP), Carestream Health (US), Konica Minolta (JP), Agfa HealthCare (BE) |
| Segments Covered | Application, End Use, Technology, Patient Demographics, Pricing Model |
| Key Market Opportunities | Advancements in imaging technology enhance diagnostic accuracy in the Digital Breast Tomosynthesis Market. |
| Key Market Dynamics | Technological advancements and regulatory support drive the adoption of Digital Breast Tomosynthesis in diagnostic imaging. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Digital Breast Tomosynthesis Market by 2035?**
A: The projected market valuation for the Digital Breast Tomosynthesis Market is expected to reach 13078.6 USD Million by 2035.

**Q: What was the market valuation of the Digital Breast Tomosynthesis Market in 2024?**
A: The overall market valuation of the Digital Breast Tomosynthesis Market was 3880.0 USD Million in 2024.

**Q: What is the expected CAGR for the Digital Breast Tomosynthesis Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Digital Breast Tomosynthesis Market during the forecast period 2025 - 2035 is 11.68%.

**Q: Which companies are considered key players in the Digital Breast Tomosynthesis Market?**
A: Key players in the Digital Breast Tomosynthesis Market include Hologic, GE Healthcare, Siemens Healthineers, Philips, Fujifilm, Canon Medical Systems, Carestream Health, Konica Minolta, and Agfa HealthCare.

**Q: What are the primary applications of Digital Breast Tomosynthesis?**
A: The primary applications of Digital Breast Tomosynthesis include Screening, Diagnostic, and Research, with projected valuations of 4000.0, 6000.0, and 3078.6 USD Million respectively by 2035.

**Q: How is the Digital Breast Tomosynthesis Market segmented by end use?**
A: The market is segmented by end use into Hospitals, Diagnostic Imaging Centers, and Specialty Clinics, with projected valuations of 4000.0, 4000.0, and 5000.0 USD Million respectively by 2035.

**Q: What technologies are utilized in the Digital Breast Tomosynthesis Market?**
A: Technologies utilized in the Digital Breast Tomosynthesis Market include Digital Radiography, Computed Tomography, and Magnetic Resonance Imaging, with projected valuations of 5500.0, 4200.0, and 4300.0 USD Million respectively by 2035.

**Q: How does patient demographics influence the Digital Breast Tomosynthesis Market?**
A: Patient demographics influence the market through segments such as Age Group, Gender, and Risk Factors, with projected valuations of 3500.0, 4000.0, and 5500.0 USD Million respectively by 2035.

**Q: What pricing models are prevalent in the Digital Breast Tomosynthesis Market?**
A: Prevalent pricing models in the Digital Breast Tomosynthesis Market include Pay-per-Use, Subscription-Based, and One-Time Purchase, with projected valuations of 4000.0, 4000.0, and 5078.6 USD Million respectively by 2035.

**Q: What trends are shaping the future of the Digital Breast Tomosynthesis Market?**
A: Trends shaping the future of the Digital Breast Tomosynthesis Market include advancements in technology and increasing demand for early detection, potentially driving market growth during the forecast period.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/digital-breast-tomosynthesis-market-60427*